AZN · NYSE · STOCK
AstraZeneca PLC
$158.74
52W $145.80 – $212.71
56/100
$246.20B
23.8
0.21
Is AZN Bullish or Bearish?
Mixed.
Innellis AI committee rates AstraZeneca PLC (AZN) Watch with a composite score of 56/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.32 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.68 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.36 means this name should amplify a favorable market regime — Macro
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Current ratio of 0.94 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 77%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 21.7% shows genuine earnings power backing the valuation
− Price-to-book of 5.9x prices in significant intangible value
Growth Analyst
bullish
62
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ EPS growing 25.9% YoY
Technical Analyst
neutral
49
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement
− Price structure making lower highs and lower lows
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.94 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
55
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
33.8
Neutral
MACD Histogram
-0.355
Bearish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Mixed
Bollinger %B
0.15
Inside Bands
Price vs Moving Averages
EMA 9
$162.32
Below
EMA 21
$166.72
Below
EMA 50
$173.66
Below
EMA 200
$184.25
Below
Fundamental Analysis
Valuation
71
Profitability
94
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
23.8×
P/B Ratio
4.91×
PEG Ratio
1.01
Dividend Yield
1.32%
52W High
$212.71
52W Low
$145.80
Quality & Growth
ROE
2107.2%
ROA
899.0%
Gross Margin
7926.9%
Operating Margin
2268.6%
Revenue Growth YoY
—
Debt / Equity
0.64
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 23.8 (inexpensive relative to a 15-40x range); Price-to-book of 4.9x; PEG ratio of 1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 21.1%; Return on assets of 9.0%; Net margin of 17.0%; Gross margin of 79.3%; Current ratio of 0.89 (tight short-term liquidity); Debt-to-equity of 0.64; Free cash flow per share is positive (5.44); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full AZN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →